Clene

Clene Debt Growth

The Year-over-Year Debt Growth of Clene (CLNN) as of Nov 16, 2026 is 3.98 %. In the previous year, Year-over-Year Debt Growth was -35.19 % — a change of -111.32% (higher).

Debt Growth

3.98 %

YoY

-111.32%

Last updated:

Year-over-Year Debt Growth of Clene is 2025 3.98 % . Year-over-Year Debt Growth of Clene was 2024 -35.19 % . It decreases by -111.32% higher compared to the previous year.

The Clene Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2019
-10.70 USD
Jan 1, 2020
50.16 USD
Jan 1, 2021
456.14 USD
Jan 1, 2022
32.37 USD
Jan 1, 2023
1.06 USD
Jan 1, 2024
-35.19 USD
Jan 1, 2025
3.98 USD
The Clene Debt Growth history
YEARDebt GrowthYoY
3.98 %-111.32%
-35.19 %-3,423.27%
1.06 %-96.73%
32.37 %-92.90%
456.14 %+809.44%
50.16 %-568.71%
-10.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Year-over-Year Debt Growth of Clene is 3.98 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Clene since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Clene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Clene

All Key Metrics — Clene